Since the NITD's establishment in 2002, its core strategy has been to collaborate with other organizations to develop and deliver life-saving treatments to those who need them," said Paul Herrling, chairman of NITD and head of Corporate Research at Novartis.
Under the collaboration, the NITD and the TB Alliance will share information on new and ongoing TB drug discovery projects.
We are confident our collaboration with NITD will not only produce promising anti-TB drug candidates, but will serve as an industry model in combining resources, expertise and willpower to tackle one of the greatest public health threats of our time.
The new collaboration supports the overall mission of both the NITD and the TB Alliance, as they are committed to improving access to medicines and helping reduce the overall global TB disease burden.
The NITD relies on establishing key partnerships to augment its research activities and recognizes the importance of such partnerships, such as the TB Alliance, to help support the advancement of drug discovery for neglected disease under its not-for-profit mission statement.
Since its launch in 2003, the NITD pledged to partner with the TB Alliance and committed that the Novartis Group intends to make the resulting treatments readily available to poor patients without profit in those developing countries where the disease is endemic.
This undertaking is tangible proof of our commitment and demonstrates the vision inherent to the NITD," said Dr.
The NITD will design, synthesize and optimize a series of nitroimidazopyran analogs for TB indication, tapping its broad medicinal chemistry expertise, know-how and biological evaluation capacity.